



Corrigendum

High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer

MS Tallman, AW Rademaker, L Jahnke, SG Brown, A Bauman, C Mangan, C Kelly, H Rubin, MS Kies, J Shaw, K Kiel, LI Gordon, WJ Gradishar and JN Winter

Bone Marrow Transplantation 1997; **20**: 721–729

Since publication the author has noticed an error in Table 3 of the above paper. The heading 'No Post-transplant CSF' refers only to the first BM column and the heading 'Post-transplant CSF' refers to columns 2, 3 and 4. A corrected version of Table 3 follows.

Table 3 Median number of days to engraftment of leukocytes and platelets according to post-transplant CSF support and source of progenitor cells

| | <i>No Post-transplant CSF</i> | | <i>Post-transplant CSF</i> | | <i>All patients (n = 48)</i> |
|-----------|-------------------------------|--------------------|----------------------------|--------------------------|----------------------------------|
| | <i>BM (n = 15)</i> | <i>BM (n = 15)</i> | <i>PBPC (n = 15)</i> | <i>BM + PBPC (n = 3)</i> | |
| ANC | 15 | 11 ^b | 10 ^b | 11 | 11.5 |
| Platelets | 22 | 14 | 12 ^b | 10 | 14.5 ^a |

ANC = absolute neutrophil count; BM = bone marrow; PBPC = peripheral blood progenitor cells; CSF = colony-stimulating factor.

^aExcludes one patient who died on day 42 of hemorrhage due to refractory thrombocytopenia despite trilineage engraftment and a second patient who developed PD at day 91 and had persistent thrombocytopenia requiring platelet transfusions (no marrow done at this time).

^bSignificantly different from no post-transplant CSF ($P < 0.0083$).